InSilico Medicine Cayman TopCo (03696) maintained an authorized share capital of USD 635, comprising 1,270,000,000 ordinary shares at a par value of USD 0.0000005 each. As of January 31, 2026, the company reported an increase in its issued ordinary shares (excluding treasury shares) from 557,418,500 to 571,622,000, reflecting an addition of 14,203,500 shares.

The company confirmed compliance with its minimum public float requirement of 15%. Share issuance activity included a full exercise of the Over-allotment Option on January 21, 2026, involving 14,203,500 shares issued at HKD 24.05.

Under the relevant equity incentive plans, 31,595,520 share options were outstanding at the end of the prior month, with 24,058 options lapsed, leaving 31,571,462. The company also reported a Post-IPO Share Option Scheme and RSU Scheme, with no newly issued shares during January 2026 but a continuing ability to issue shares under these plans.